Transgender Flashcards

1
Q

List the biochemical goals of hormone therapy in transgender care

A
  1. Suppress endogenous sex hormone production
  2. Maintain sex hormone levels within the normal range for the person’s affirmed gender
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What tanner stage should you start treatment of transgender patients with Lupron?

A

Tanner 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When should you start treatment of transgender patients with gender affirming hormones?

A

When a multidisciplinary team has confirmed the persistence of gender dysphoria AND sufficient mental capacity to give informed consent (typically age 16, minimal published studies in age 13.5-14)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How often should transgender patients be monitored clinically and with lab evaluation while on pubertal suppression?

A
  • Every 3-6 months: height, weight, sitting height, blood pressure, Tanner staging
  • Every 6-12 months: lab tests (LH, FSH, estradiol/testosterone, 25 OH vitamin D)
  • Every 1-2 years: DEXA scan, bone age x-ray
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

When should gender-affirming surgery be considered?

A

After at least 1 year of consistent and compliant hormone treatment (unless hormone therapy is contraindicated or not desired)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

At what age can you consider gender-affirming surgery with gonadectomy/hysterectomy in transgender patients?

A
  • Age 18 or the age of majority in the patient’s country
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define gender dysphoria

A

Persons who are not satisfied with their designated gender (APA definition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The prevalence of gender dysphoria in individuals with 46,XX CYP21A2 CAH is ______ than the baseline population prevalnce

A

higher

This supports the concept that gender identity is impacted by androgen exposure in-utero

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What percentage of pre-pubertal children with gender dysphria persist into adolescence?

A

15%

More likely to persist if it is extreme dysphoria or if they have socially transitioned

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the DSM5 criteria for GD in adolescents and adults?

A

A) Marked incongruence between one’s experienced vs. natal gender of at least 6 months, manifested by 2+ of:

  • incongruence between experienced gender and primary/secondary sex characteristics
  • desire to be rid of primary/secondary sex characteristics
  • desire for sex characteristics of the other gender
  • desire to be of the other gender
  • desire to be treated as the other gender
  • conviction that one has typical feelings/reactions of the other gender

B) Condition is associated with distress or impairment in functioning

Specify if: associated with DSD, or post-transition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What factors may contribute to post-operative regret in transgender patients?

A
  • Poor quality of surgery
  • Severe psychiatric comorbidity
  • Lack of support
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List the eligibility criteria for transgender adolescents to proceed with gender-affirming hormone therapy

A
  • Qualified MPH has confirmed (1) the persistence of GD (2) Any coexisting psychological, medical or social problems have been addressed and (3) Adolescent has sufficient mental capacity to consent to this potentially irreversible treatment
  • Adolescent (1) has been informed of effects of treatment and (2) has given informed consent
  • Endocrinologist (1) agrees with the indication and (2) has confirmed no medical contraindications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When should counselling about fertility preservation be done in transgender patients?

A
  • Before pubertal suppression (adolescents) or before cross-sex hormone therapy (adolescents and adults)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List 2 advantages to starting puberty-blocking early (T2) in transgender adolescents

A
  • Improved physical outcome (prevent undesirable secondary sexual characteristics)
  • Improved psychological experience
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which secondary sex characteristics are irreversible after pubertal progression in males and females?

A
  • Males: Adam’s apple, low voice, male bone configuration (large jaw, big feet and hands), tall stature
  • Females: breasts, female body habitus, relatively short stature
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the risks of pubertal suppresion in adolescents with gender dysphoria?

A
  • Poor bone mineralization (decreased BMD Z scores)
  • Hot flashes, fatigue, mood alterations
  • Compromised fertility IF subsequently treated with sex hormones
  • Unknown effects on brain development
  • Possibly increased fat mass/decreased lean body mass
  • Arterial hypertension (reported in precocious puberty)
17
Q

What can you do to improve bone health in transgender adolescents on Lupron?

A
  • Calcium suppplement
  • Vitamin D supplement
  • Physical activity
18
Q

List 3 adverse effects from excess testosterone therapy

A
  • Erythrocytosis
  • Sleep apnea
  • Lipid changes
  • Hypertension
  • Excessive weight gain
  • Salt retention
  • Excessive/cystic acne
19
Q

How often should transgender patients be monitored clinically and with lab evaluation while on gender-affirming hormone therapy?

A
  • Every 3-6 months: height, weight, sitting height, blood pressure, Tanner staging
  • Every 6-12 months: lab tests (TG males = hemoglobin/hematocrit, lipids, testosterone, 25 OH vitamin D, TG females = prolactin, estradiol, 25 OH vitamin D)
  • Every 1-2 years: DEXA scan, bone age x-ray
20
Q

What physical changes can you expect in the first 6 months of testosterone therapy in transgender males? 1 year?

A
  • 6 MONTHS:
    • Cessation of menses
    • Increased sexual desire
    • Increased facial and body hair
    • Increased oiliness of skin
    • Increase muscle
    • Restribution of body fat
  • 1 YEAR:
    • Deepening of voice
    • Clitoromegaly
    • Male pattern hair loss (if genetically predisposed)
21
Q

What physical changes can you expect in the first 12 months of estrogen/antiandrogen therapy in transgender females? 2 years?

A
  • 1 YEAR:
    • Decreased sexual desire
    • Decreased spontaneous erections
    • Decreased facial and body hair
    • Decreased oiliness of skin
    • Increased breast tissue growth
    • Redistribution of fat mass
  • 2 YEARS:
    • Maximal breast development
    • Prostate and testicular atrophy (after prolonged treatment)
22
Q

List 3 adverse effects from excess estrogen therapy

A
  • Thromboembolic disease (20-fold increase)
  • Liver dysfunction
  • Hypertension